NCT06836141 Biomarkers for Cognitive Decline in Intracerebral Hemorrhage
| NCT ID | NCT06836141 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rush University Medical Center |
| Condition | Primary Intracerebral Hemorrhage |
| Study Type | OBSERVATIONAL |
| Enrollment | 118 participants |
| Start Date | 2025-08-02 |
| Primary Completion | 2029-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 118 participants in total. It began in 2025-08-02 with a primary completion date of 2029-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to see if silent brain infarcts (SBIs), or stroke-like symptoms detectable during brain imaging, are a possible contributor to cognitive decline for patients diagnosed with spontaneous intracerebral hemorrhage (sICH), or blood clot in the brain. The main questions it aims to answer are * if SBIs in sICH are associated with a lower cognitive level and more rapid cognitive decline * if SBIs in sICH are associated with certain findings on brain imaging * if SBIs in sICH are associated with higher inflammation measured by certain blood tests Participants will undergo * cognitive testing during hospitalization, and at 3, 6 and 12 months after the sICH * Magnetic Resonance Imaging (MRI) of the brain during hospitalization and 12 months after the sICH * blood draws during hospitalization and at 3, 6 and 12 months after the sICH
Eligibility Criteria
Inclusion Criteria: * Primary Intracerebral Hemorrhage * Age ≥ 18 and \< 80 years Exclusion Criteria: * Pre-existing dementia
Contact & Investigator
Rajeev Garg, MD
PRINCIPAL INVESTIGATOR
Rush University Medical Center
Frequently Asked Questions
Who can join the NCT06836141 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Primary Intracerebral Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06836141 currently recruiting?
Yes, NCT06836141 is actively recruiting participants. Contact the research team at Amanda_C_Sremac@rush.edu for enrollment information.
Where is the NCT06836141 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06836141 clinical trial?
NCT06836141 is sponsored by Rush University Medical Center. The principal investigator is Rajeev Garg, MD at Rush University Medical Center. The trial plans to enroll 118 participants.